Search Results

Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced the presentation of key data supporting dry AMD pipeline candidates, including the company’s risuteganib (Luminate®), this morning at Bascom Palmer Eye Institute’s 20th annual Angiogenesis, Exudation and Degeneration meeting.

Allegro Ophthalmics, LLC today announced that the Company has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design of its Phase 2b/3 clinical trial of risuteganib (Luminate®) for the treatment of intermediate, non-exudative age-related macular degeneration (dry AMD).

Integrated Oncology Network, LLC (“ION”), a portfolio company of Silver Oak Services Partners, LLC (“Silver Oak”), today announced the acquisition of Urology Partners, LLC.